These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32416253)

  • 1. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
    Mei M; Tsai NC; Mokhtari S; Al Malki MM; Ali H; Salhotra A; Sandhu K; Khaled S; Smith E; Snyder D; Marcucci G; Forman SJ; Pullarkat V; Stein A; Aldoss I; Nakamura R
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1425-1432. PubMed ID: 32416253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
    Rodriguez R; Nakamura R; Palmer JM; Parker P; Shayani S; Nademanee A; Snyder D; Pullarkat V; Kogut N; Rosenthal J; Smith E; Karanes C; O'Donnell M; Krishnan AY; Senitzer D; Forman SJ
    Blood; 2010 Feb; 115(5):1098-105. PubMed ID: 19965688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
    Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA
    Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
    Cho BS; Lee S; Kim YJ; Chung NG; Eom KS; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Kim CC
    Leukemia; 2009 Oct; 23(10):1763-70. PubMed ID: 19440217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.
    Peric Z; Labopin M; Peczynski C; Polge E; Cornelissen J; Carpenter B; Potter M; Malladi R; Byrne J; Schouten H; Fegueux N; Socié G; Rovira M; Kuball J; Gilleece M; Giebel S; Nagler A; Mohty M
    Bone Marrow Transplant; 2020 Aug; 55(8):1560-1569. PubMed ID: 32361712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
    Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using
    Mei M; Palmer J; Tsai NN; Simpson J; O'Hearn J; Stein A; Forman S; Spielberger R; Cai JL; Htut M; Nakamura R; Al Malki MM; Herrera A; Wong J; Nademanee A
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e268-e276. PubMed ID: 37301631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression in patients with acute lymphoblastic leukemia - update of single center study.
    Raida L; Kuba A; Rusinakova Z; Szotkowska R; Skoumalova I; Faber E; Szotkowski T; Rohon P; Hubacek J; Indrak K; Pikalova Z; Jarosova M; Divoka M; Langova K; Papajik T
    Neoplasma; 2017; 64(5):762-769. PubMed ID: 28592129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
    Salhotra A; Mei M; Stiller T; Mokhtari S; Herrera AF; Chen R; Popplewell L; Zain J; Ali H; Sandhu K; Budde E; Nademanee A; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):287-292. PubMed ID: 30227232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
    Stein AS; Palmer JM; O'Donnell MR; Kogut NM; Spielberger RT; Slovak ML; Tsai NC; Senitzer D; Snyder DS; Thomas SH; Forman SJ
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1407-14. PubMed ID: 19822300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
    Patel K; Parmar S; Shah S; Shore T; Gergis U; Mayer S; van Besien K
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):456-61. PubMed ID: 26524732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.
    Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1177-1185. PubMed ID: 28396159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
    Fox ML; García-Cadenas I; Pérez AM; Villacampa G; Piñana JL; Ortí G; Montoro J; Roldán E; Bosch Vilaseca A; Martino R; Salamero O; Saavedra S; Hernandez-Boluda JC; Esquirol A; Sierra J; Sanz J; Solano C; Bosch F; Barba P; Valcarcel D
    Leuk Lymphoma; 2020 Aug; 61(8):1823-1832. PubMed ID: 32654570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.